Celgene's Hugin: Drug Prices Should Be Fair

The transcript discusses Celgene's approach to drug pricing, emphasizing value-based pricing and the importance of offering value to patients and payers. It highlights Celgene's growth strategy, focusing on R&D investments and a strong pipeline. The conversation also touches on potential changes in the healthcare system, with a call for continuous evolution and refinement to meet future demands.

In what ways does the speaker believe the healthcare system needs to evolve over the next 25 years?

What is the speaker's perspective on the politicization of healthcare, particularly in relation to Obamacare?